Dosage Forms

Micronization and other processes are used to obtain optimal particle characteristics for pulmonary and oral solid-dosage delivery.

A GPhA report says generic drugs saved the US health system $239 billion in 2013.

Molecular Profiles has expanded its capsule filling capability following significant investment into new equipment at its clinical manufacturing site in the United Kingdom.

FDA approved XTANDI for the treatment of metastatic castration-resistant prostate cancer.

PDA will publish a technical report on quality risk management aspects of drug shortages in early 2015.

PDA surveys are designed to evaluate quality metrics practices at member organizations.

FDA gives NewLink Genetics approval to proceed to Phase 1 clinical studies of Ebola vaccine.

Conventional tablets may no longer be the go-to solution.

Advances in engineered particles and the subsequent reduction in the API mass required to achieve a therapeutic dose can lead to a reduction in side effects.

The role of add-on devices and how they affect drug delivery with a pressurized metered dose inhaler.

A surge in generic drug applications is testing FDA?s ability to reduce the backlog of ANDAs.

The National Institute of Allergy and Infectious Diseases will begin the first in a series of trials for an Ebola vaccine during the week of Sept. 1.

Concerns about quality in overseas production may bring generic drug production back to the United States, concludes CPhI study.

The European system for assessing drugs will be used as a model internationally.

EMA has released the second module of a new guideline on influenza vaccines for a six-month public consultation. The guidance covers the non-clinical and clinical requirements for the development of new influenza vaccines and aims to facilitate the prompt assessment of new vaccines. It follows the publication of a module on the quality requirements.

Customers are looking to reduce risk, increase performance, and optimize productivity.

FDA seeks high quality applications and products to facilitate approvals and reduce safety and supply problems.

Experts from Capsugel and Catalent discuss the rationale of using lipid0basd formulations to improve the oral bioavailability of poorly soluble drugs.

With a number of branded biologics hanging at the patent cliff, the future looks promising for biosimilars.

Innovative therapeutic approaches beyond mAbs will require new methods for future facility construction.

Tool coatings are now seen as an acceptable means of solving production problems, such as sticking and corrosion, resulting in increased product yield.

Efforts to tackle challenges in tablet manufacture are shaped by quality by design (QbD) and continuous manufacturing.

To realise the full potential for biosimilars, stakeholders must build a better understanding of biosimilars and to take a comprehensive view of how these important medicines can fit into treatment pathways.

Stephen Tindal from Catalent Pharma Solutions speaks with Pharmaceutical Technology Europe about advances in softgel technologies.

Softgels are now being recognised as one of the preferred dosage forms for the treatment of pain, eye conditions, cough and cold, as well as allergy.

Representatives of contract service organizations that develop biologic-based drugs discussed technology trends such as high-throughput screening and single-use systems.

Representatives of contract service organizations that specialize in parenteral drug development and manufacturing describe the evolving trends.

Contract development and manufacturing organizations identify trends, challenges, and emerging technology and service needs for solid and semi-solid dosage forms.

Pfizer announced an agreement to acquire Baxter International?s marketed vaccines for $635 million.

Redbiotec and GE Healthcare Life Sciences develop a novel manufacturing process for virus-like particles.